Filing Flows

Filing Flows › Charles River Laboratories International (CRL) › Next earnings date

Charles River Laboratories International (CRL) earnings: beat the estimate

Charles River Laboratories International (CRL) reported on Nov 4, 2026 and beat the EPS estimate: $3.09 against $2.98 (+3.5%). Revenue was $983M for Q3 2026, -2% year over year. It beat the EPS estimate in 100% of the quarters on record.

Last result+3.5% vs estimate
Beat rate100%

The last report

Charles River Laboratories International reported revenue of $983M for the third quarter 2026 (-2% Y/Y), net earnings $333M: DSA $596M, RMS $208M, Manufacturing $179M. How it makes money → · Every quarter →

Charles River Laboratories International: EPS against the estimate, last 5 reportsCharles River Laboratories International: EPS against the estimate, last 5 reportsEstimateReported$2.34$2.43Nov 25$2.35$2.39Feb 26$1.95$2.06May 26$2.74$3.02Aug 26$2.98$3.09Nov 26
Latest (Nov 26): Estimate $2.98, Reported $3.09.
CRL: the stock's move on each reportCRL: the stock's move on each reportAug 5, 2026+13.4%May 7, 2026-2.3%Feb 18, 2026+3.6%Nov 5, 2025-3.9%

Charles River Laboratories International's latest quarter

Charles River Laboratories International, Q3 2026: revenue $983M (-2% year over year), operating margin 20.6%, net earnings $333M, operating cash flow $254M. The chart follows the revenue to costs, profit and cash.

Questions

Did Charles River Laboratories International beat earnings?

Charles River Laboratories International (CRL) reported on Nov 4, 2026 and beat the EPS estimate: $3.09 against $2.98 (+3.5%).

When does CRL report earnings?

The next date is not set yet.

Does Charles River Laboratories International usually beat earnings?

It beat the consensus EPS estimate in 100% of the quarters on record.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.